Tempus AI, Inc. TEM recently announced the acquisition of Deep 6 AI, a leading artificial intelligence (AI) company ...

For the full year, the Data and Services division was a key contributor. The acquisition of Ambry Genetics, finalized in February 2025, further strengthens Tempus’ genomics capabilities by adding a ...

Tempus AI's Q4 financials were slightly below expectations but aligned with preliminary results. See why I remain bullish on TEM stock.

Tempus announced its acquisition of Ambry Genetics for $375 million in cash and $225 million in shares at closing in November and the deal closed earlier this month. Ambry will continue to operate ...

Cathie Wood’s ARK Investment continues to capitalize on the pullback in Tempus AI (TEM) stock by accumulating more shares, ...

Tempus AI's slowing growth, cash flow issues, and net debt raise doubts about its sustainability. Explore key concerns and market outlook.

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today reported financia ...

A remarkable start to the year, marked by a 160% surge, has had investors paying close attention to healthcare tech company ...

Acquisition: Closed the acquisition of Ambry Genetics on February 3. Google Agreement: Extended for another five years. Tempus AI Inc (NASDAQ:TEM) reported a 35.8% year-over-year revenue growth in ...

The financing is intended to support Tempus’ previously announced acquisition of Ambry Genetics (“Ambry”), which closed on February 3, 2025. Combined with $260 million of capital provided in ...

The acquisition of Ambry Genetics, finalized in February 2025, further strengthens Tempus’ genomics capabilities by adding a West Coast lab and expanding inherited risk testing. Another ...